The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases.
A hallmark of autoimmune diseases is the production of autoantibodies against intracellular autoantigens. Although their pathogenetic and their etiologic relationship are not fully understood, these autoantibodies are important tools for establishing the diagnosis, classification and prognosis of autoimmune diseases. Systemic rheumatic diseases are among the most complex disorders because their clinical presentation and constellation of findings are in part reflected by the wide spectrum of autoantibodies found in the sera of patients suffering from these disorders. These autoantibodies usually target large complexes consisting of protein antigens noncovalently associated with (ribo)-nucleic acid(s), like the spliceosome or Ro/La-RNPs. In this review, we first address the main characteristics and the clinical value of several autoantibodies, with respect to their diagnostic sensitivity and specificity. Subsequently, we provide a brief overview of the antigenic determinant types that have been identified on the corresponding autoantigens. The antibody targets of autontigens include primary, secondary, tertiary and quarternary structure epitopes, as well as cryptotopes, neoepitopes and mimotopes. We next focus on antigenic structures corresponding to B-cell epitopes with high disease specificity and sensitivity for all the major autoantigens in systemic autoimmunity including the Ro/La and U1 ribonucleoprotein complexes and the Ku70/80, ribosomal P, DNA topoisomerase I, filaggrin, Jo-1 and PM/SCl-100 autoantigens. These epitopes, defined at the peptide level, can be chemically synthesized and engineered for the development of new inexpensive and easier to perform assays and the improvement of the methods for autoantibody detection. Specific examples of newly developed assays that incorporate (i) epitopes with high disease specificity and sensitivity, (ii) modified epitopes, (iii) conformational epitopes and (iv) complementary epitopes are discussed in detail. Finally, we examine the potential of combining these synthetic epitopes for future development of multiplex diagnostic tests based on miniaturized autoantigen arrays.
Routsias
John G
JG
Department of Pathophysiology, School of Medicine, University of Athens, 75, M Asias St., 11527 Athens, Greece.
Tzioufas
Athanasios G
AG
Moutsopoulos
Haralampos M
HM
D001324:Autoantigens / Q000276:immunology*; D018604:Epitope Mapping / Q000379:methods; D018985:Epitopes, B-Lymphocyte / Q000737:chemistry / Q000276:immunology*; D000091344:Filaggrin Proteins; D006801:Humans; D010455:Peptides / Q000737:chemistry / Q000276:immunology; D012216:Rheumatic Diseases / Q000175:diagnosis / Q000276:immunology*; D012680:Sensitivity and Specificity
D001324:Autoantigens; D018985:Epitopes, B-Lymphocyte; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D010455:Peptides